Illumina Inc. announced the launch of DRAGEN™ version 4.4 software (v4.4) on May 13, 2025, positioning it as the industry's most comprehensive secondary analysis solution. The latest version introduces out-of-the-box oncology applications for clinical research and enhanced support for newly announced Illumina multiomics assays.
DRAGEN v4.4 delivers a 30% improvement in germline structural variant calling accuracy, building on its reputation for unparalleled performance. This enhancement simplifies NGS analysis for customers and expands their capabilities in complex genomic data interpretation.
The University Hospital of Tübingen in Germany has selected DRAGEN for a pioneering study to evaluate the clinical utility of advanced secondary analysis on whole-genome germline testing. This adoption highlights DRAGEN's role in providing high-accuracy variant calling, which is critical for identifying inherited genetic mutations and informing precision medicine.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.